Company: INMB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001213900-25-041072
Chunk: 3

Company: Inmune Bio, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
  
    Amount  
    Capital  
    Income (Loss)  
    Deficit  
    Equity 
  
    Balance as of December 31, 2023 
     17,950,776  
    $18  
    $159,143  
    $(799) 
    $(121,022) 
    $37,340 
  
    Stock-based compensation 
     -  
     -  
     1,779  
     -  
     -  
     1,779 
  
    Gain on foreign currency translation 
     -  
     -  
     -  
     130  
     -  
     130 
  
    Net loss 
     -  
     -  
     -  
     -  
     (11,025) 
     (11,025)
  
    Balance as of March 31, 2024 
     17,950,776  
    $18  
    $160,922  
    $(669) 
    $(132,047) 
    $28,224 

The accompanying
notes are an integral part of these unaudited condensed consolidated financial statements.

4

INMUNE BIO INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

    For the Three Months Ended March 31, 

    2025  
    2024 
  
    CASH FLOWS FROM OPERATING ACTIVITIES: 

    Net loss 
    $(9,739) 
    $(11,025)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Stock-based compensation 
     2,076  
     1,779 
  
    Accretion of debt discount 
     -  
     34 
  
    Changes in operating assets and liabilities: 

    Research and development tax credit receivable 
     (102) 
     (228)
  
    Other tax receivable 
     95  
     (20)
  
    Prepaid expenses 
     124  
     401 
  
    Prepaid expenses – related party 
     -  
     119 
  
    Other assets 
     30  
     25 
  
    Accounts payable and accrued liabilities 
     659